| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Neurocrine Biosciences Inc. | INGREZZA - (T-Force GOLD) | Tourette syndrome - juvenile | Phase 2b | Withdrawn | oral | Neurology |
| Neurocrine Biosciences Inc. | NBI-1065890 | CNS Indications | Phase 2 | Ongoing | Oral | Neurology |
| Neurocrine Biosciences Inc. | NBI-1070770 | Major Depressive Disorder | Phase 2 | Data Released | Oral | Psychiatric |
| Neurocrine Biosciences Inc. | Crinecerfont - (adolescent open-label) | Classic congenital adrenal hyperplasia (CAH) | Phase 2 | Data Released | Oral | Genetic Disorder |
| Neurocrine Biosciences Inc. | NBI-921352 | Focal Onset Seizure in Adults | Phase 2 | Withdrawn | Oral | Neurology |
| Neurocrine Biosciences Inc. | NBI-827104 | Essential Tremor | Phase 2 | Trial Completed | Oral | Neurology |
| Neurocrine Biosciences Inc. | Luvadaxistat (NBI-1065844) | Cognitive Impairment Associated with Schizophrenia (CIAS) | Phase 2 | Data Released | Oral | Psychiatric |
| Neurocrine Biosciences Inc. | VY-AADC02 - (RESTORE-1) | Parkinson's Disease | Phase 2 | Trial Discontinued | Intracerebral | Neurology |